THE INDIAN PHARMACIST Official Circular Pharmacy LogoTHE INDIAN PHARMACISTLearn. Explore. Practise. Excel.
Disease & Clinical Pharmacy Guides • 3-TIER LEARNING GUIDE

Tuberculosis Pharmacotherapy in India: NTEP Daily FDCs, Hepatotoxicity & BPaLM Regimen

Editorial Body: THE INDIAN PHARMACIST Editorial Reference Reading Time: 9 min read Published: 2026-01-15 Last Updated: 2026-11-08 Status: Evidence-Sourced Educational Guide

1. Level 1 — Quick Learning Overview & Core Definition

Quick Concept Summary: Under India's National Tuberculosis Elimination Programme (NTEP), drug-sensitive pulmonary tuberculosis (DS-TB) is treated for 6 months using weight-band daily Fixed-Dose Combinations (FDCs): a 2-month Intensive Phase of Isoniazid (H), Rifampicin (R), Pyrazinamide (Z), and Ethambutol (E) [2HRZE], followed by a 4-month Continuation Phase of Isoniazid, Rifampicin, and Ethambutol [4HRE].

2. Level 2 — Standard Study: Underlying Process & Major Classifications

Mycobacterium tuberculosis exists in distinct metabolic subpopulations within pulmonary cavities, macrophages, and caseous granulomas: rapidly dividing extracellular bacilli (killed rapidly by Bactericidal Isoniazid), semi-dormant bacilli undergoing sporadic metabolic bursts (sterilised by Rifampicin), and intracellular bacilli in acidic phagolysosomes (preferentially killed by Pyrazinamide).

Major Pharmacological & Scientific Classifications

  • Isoniazid (INH): Prodrug activated by bacterial KatG catalase-peroxidase; inhibits InhA (mycolic acid cell-wall synthesis). Causes peripheral neuropathy via pyridoxine (Vitamin B6) depletion.
  • Rifampicin (RIF): Inhibits bacterial DNA-dependent RNA polymerase (rpoB). Potent CYP3A4/2C9/2C19/P-gp inducer; causes harmless orange-red discolouration of urine, sweat, and tears.
  • Pyrazinamide (PZA): Converted by pyrazinamidase (pncA) to pyrazinoic acid; causes hyperuricaemia/arthralgia and dose-related hepatotoxicity.
  • Ethambutol (EMB): Inhibits arabinosyl transferase (embB); bacteriostatic; causes dose-related retrobulbar optic neuritis (red-green colour blindness and reduced visual acuity).
  • MDR/RR-TB BPaLM Regimen: Bedaquiline + Pretomanid + Linezolid + Moxifloxacin (6-month all-oral regimen).

3. Original Scientific Illustration (PLATE-8.9: 8.9 Antibiotic Mechanisms of Action: Cell-Wall Synthesis, Ribosomal 30S/50S Protein Synthesis, DNA Gyrase & Folate Pathway)

ANTIBACTERIAL MECHANISMS OF ACTION: CELL WALL, 30S/50S RIBOSOME, DNA & FOLATE 1. Cell-Wall Synthesis (Bactericidal) • Beta-Lactams (Penicillins, Cephalosporins, Meropenem): Inhibit PBPs (Transpeptidase) • Vancomycin: Binds D-Ala-D-Ala peptide • Fosfomycin: Inhibits MurA enolpyruvyl PK/PD: Time-dependent (fT > MIC) 2. 30S Ribosomal Subunit • Aminoglycosides (Gentamicin, Amikacin): Irreversible 30S binding & mRNA misreading (Bactericidal; Cmax/MIC; Ototoxic/Nephrotoxic) • Tetracyclines (Doxycycline) & Tigecycline: Block aminoacyl-tRNA binding at 30S A-site 3. 50S Ribosomal Subunit • Macrolides (Azithromycin, Clarithromycin) & Clindamycin: Block 23S rRNA translocation • Linezolid: Blocks 70S initiation complex (MRSA/VRE) • Chloramphenicol: Inhibits peptidyl transferase Mostly bacteriostatic (Linezolid vs Staph/Strep) 4. Nucleic Acid Synthesis (DNA Gyrase & RNA Pol) • Fluoroquinolones (Ciprofloxacin, Levofloxacin, Moxifloxacin): Inhibit DNA Gyrase (Topoisomerase II) & Topoisomerase IV (Bactericidal) • Rifampicin: Inhibits bacterial DNA-dependent RNA polymerase (β-subunit) • Metronidazole: Reduced nitro group forms free radicals that strand-break DNA 5. Folate Pathway & Cell Membrane Disruptors • PABA → [Sulfamethoxazole blocks Dihydropteroate Synthase] → Dihydrofolate • Dihydrofolate → [Trimethoprim blocks DHFR] → Tetrahydrofolate (Co-trimoxazole) • Polymyxins (Colistin): Bind LPS outer membrane of MDR Gram-negative bacilli • Daptomycin: Ca2+-dependent membrane depolarisation of Gram-positive cocci (MRSA)
Figure 8.9: Mechanisms of action of major antibacterial classes across bacterial cell-wall synthesis, 30S/50S ribosomal protein translation, nucleic acid replication, and folic acid biosynthesis.
Diagram Walkthrough: Selective toxicity of antibacterial agents relies on targeting structural and biochemical pathways unique to prokaryotic bacteria. (1) Cell-Wall Synthesis Inhibitors: Beta-lactams (penicillins, cephalosporins, carbapenems, monobactams) acylate Penicillin-Binding Proteins (PBPs / transpeptidases), blocking peptidoglycan cross-linking, while Vancomycin binds the D-Ala-D-Ala terminus of nascent peptidoglycan precursors. (2) Protein Synthesis Inhibitors target bacterial 70S ribosomes (composed of 30S and 50S subunits, distinct from human 80S ribosomes): Aminoglycosides (bactericidal; cause mRNA misreading at 30S) and Tetracyclines (block aminoacyl-tRNA attachment at 30S A-site); Macrolides, Clindamycin, and Chloramphenicol target the 50S peptidyl transferase/translocation centre, while Linezolid prevents 70S initiation complex formation. (3) Nucleic Acid Inhibitors: Fluoroquinolones inhibit DNA gyrase (topoisomerase II) and topoisomerase IV; Rifampicin inhibits DNA-dependent RNA polymerase (rpoB). (4) Antimetabolites: Sulfamethoxazole inhibits dihydropteroate synthase and Trimethoprim inhibits dihydrofolate reductase in sequential synergistic blockade.

4. Level 3 — Advanced Clinical, Pharmacokinetic & Regulatory Reference

Drug-Induced Liver Injury (DILI) & Antiretroviral Co-Administration: Three first-line anti-TB agents (Pyrazinamide > Isoniazid > Rifampicin) are potentially hepatotoxic. If AST/ALT exceeds 5x Upper Limit of Normal (ULN) asymptomatically, or >= 3x ULN with jaundice/nausea/vomiting, withhold HRZ immediately, bridge with non-hepatotoxic agents (Ethambutol + Fluoroquinolone/Aminoglycoside) if clinically severe, and sequentially rechallenge once transaminases normalise. Because Rifampicin strongly induces UGT1A1 and CYP3A4, patients co-infected with HIV receiving Dolutegravir-based antiretroviral therapy (TLD) require an additional 50 mg dose of Dolutegravir 12 hours after TLD (50 mg BD total).

5. Common Misunderstandings & Clinical Pitfalls

Common Misunderstanding: Stopping anti-TB therapy when the patient's urine turns bright orange-red. Pharmacists must reassure patients upfront that Rifampicin routinely stains urine, saliva, sweat, and soft contact lenses orange-red, whereas yellowing of the sclera (jaundice) with dark tea-coloured urine and right upper quadrant pain requires urgent liver function testing.

6. Key Takeaways, Related Medicine Monographs & Calculators

Key Study & Practice Takeaways:
  • Co-prescribe Pyridoxine (Vitamin B6, 10–50 mg daily) with Isoniazid to prevent peripheral neuropathy, especially in pregnancy, diabetes, malnutrition, chronic kidney disease, and HIV.
  • Check visual acuity (Snellen chart) and red-green colour vision (Ishihara plates) before and during Ethambutol therapy.
  • Record all anti-TB prescriptions in the mandatory Schedule H1 register and ensure Nikshay portal notification.

Related Medicine Monographs

💊 Amoxicillin [8.1] →💊 Azithromycin [8.3] → ⚖️ Compare Medicines →

Related Clinical Calculators

🧮 Weight-Based Dose Calculator →🧮 Tablet & Capsule Course Quantity →

7. Authoritative Medical & Regulatory References

  1. Indian Pharmacopoeia Commission (IPC) & CDSCO: Indian Pharmacopoeia (IP 2022) & National List of Essential Medicines (NLEM 2022), Ministry of Health and Family Welfare, Government of India (https://ipc.gov.in/ & https://cdsco.gov.in/).
  2. NCBI Bookshelf / National Library of Medicine: StatPearls Pharmacology, Physiology & Clinical Therapeutics Compendia (https://www.ncbi.nlm.nih.gov/books/).
  3. DailyMed (US National Library of Medicine): Official FDA Prescribing Information & Clinical Pharmacology Labelling (US Jurisdiction Reference) (https://dailymed.nlm.nih.gov/dailymed/).
  4. MedlinePlus, NHS Health Information, Cleveland Clinic Health Library & National Institute on Aging (NIA): Structured patient education and clinical communication references (MedlinePlus • NHS • Cleveland Clinic • NIA).